[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universität des Saarlandes\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":370},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,52,83,111,133,168,191,218,240,269,301,326,349],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100502329","phase-3-acalabrutinib-in-combination-with-r-minichop-in-older-adults-with-untreated-diffuse-large-b-cell-lymphoma-100502329",false,"NCT05820841","Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma","A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination With Rituximab and Reduced Dose CHOP (R-miniCHOP) in OldEr Adults With Untreated Diffuse Large B-Cell Lymphoma","ARCHED","Inclusion Criteria:\n\nInformed consent\n\n1. Ability to understand the purpose and risks of the study and capable of giving signed informed consent which includes:\n\n   1. Compliance with the requirements and restrictions listed in the informed consent form (ICF).\n   2. Authorization to use protected health information\u002Fdata \\[in accordance with the General Data Protection Regulation (GDPR)\\].\n2. Provision of signed and dated, written ICF prior to any mandatory study specific procedures, sampling, and analyses\n3. Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules and tablets without difficulty.\n\n   Age\u002FSex\n4. Men and women \\>80 years of age or \\>60 up to 80 years of age and ineligible for full dose R-CHOP according to investigator assessment\\*.\n\n   We recommend classifying patients aged 61-80 as full-dose R-CHOP ineligible if they fulfill one of the following criteria: ADL \\\u003C5, IADL \\\u003C6, CIRS-G ≥1 score = 3, or \\> 8 score = 2.\n5. Male patients who are sexually active with women of childbearing potential (definitions see section 17.8) must agree to use highly effective forms of contraception with the addition of a barrier method (condom) during the study (see section 17.8.1) as well as to the restrictions mentioned in section 9.13.\n6. Female patients of childbearing potential (definitions see 17.8) who are sexually active must agree to use highly effective forms of contraception while on the study as well as to the restrictions mentioned in section 9.13.\n\n   Disease characteristics\n7. Histologically proven, previously untreated CD20+ diffuse large B-cell lymphoma (DLBCL) according to the 2017 WHO classification including:\n\n   1. diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS)\n   2. primary cutaneous DLBCL leg type\n   3. intravascular large B-cell lymphoma\n   4. EBV+ DLBCL, NOS\n   5. HHV8+DLBCL, NOS\n   6. primary mediastinal (thymic) large B-cell lymphoma\n   7. B-cell lymphoma, with intermediate features between DLBCL and classical Hodgkin lymphoma\n   8. follicular lymphoma grade 3B\n   9. high-grade B-cell lymphoma, NOS\n   10. high-grade B-cell lymphoma, with MYC and BCL2 and\u002For BCL6 rearrangements\n   11. T-cell\u002Fhistiocyte-rich large B-cell lymphoma\n   12. DLBCL associated with chronic inflammation\n   13. ALK+ large B-cell lymphoma\n   14. large B-cell lymphoma with IRF4 rearrangement Please note: patients in whom indolent lymphoma is diagnosed concurrently with the one of the above listed diagnoses can also be included.\n8. Disease Stage I with bulk ≥7.5cm, II, III or IV according to Ann Arbor Classification Type of patient and clinical characteristics\n9. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. An ECOG Score of 3 is acceptable only if this is directly attributable to lymphoma.\n10. Meet the following laboratory parameters:\n\n    1. Absolute neutrophil count (ANC) ≥ 1500 cells\u002Fµl or platelet count ≥ 100.000\u002Fµl unless directly attributable to lymphoma.\n    2. Serum AST and ALT ≤3 x upper limit of normal (ULN) unless directly attributable to lymphoma.\n    3. Total bilirubin ≤1.5 x ULN, unless directly attributable to Gilbert's syndrome or lymphoma.\n    4. Estimated creatinine clearance of ≥30 mL\u002Fmin, calculated by Cockcroft-Gault (using actual body weight) (if male, \\[140-Age\\] x Mass \\[kg\\] \u002F \\[72 x creatinine mg\u002FdL\\]; multiply by 0.85 if female), or serum creatinine ≤2.5 x ULN.\n\nExclusion Criteria:\n\nMedical conditions\n\n1. Evidence of disease (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension and renal transplant) that, in the investigator's opinion, make it undesirable for the patient to participate in the study or that would jeopardize compliance with the protocol \\[e.g. a single score of 4 on one single category on the CIRS-G-Score (but not a cumulative score of 4)\\].\n2. Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of randomization or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or LVEF \\\u003C 40%. Patients with controlled, asymptomatic atrial fibrillation are allowed to enroll on study.\n3. Severe pulmonary dysfunction (CTCAE grade 3 or 4) unless associated with lymphoma.\n4. Severe psychiatric or neurologic disease that, in the investigator's opinion, make it undesirable for the patient to participate in the study or that would jeopardize compliance with the protocol.\n5. Persistent neuropathy CTCAE grade 3 or 4.\n6. Refractory nausea and vomiting, inability to swallow acalabrutinib, or malabsorption syndrome; chronic severe gastrointestinal disease, gastric restrictions, or bariatric surgery such as gastric bypass; partial or complete bowel obstruction, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of study treatment.\n7. History of prior malignancy that could affect compliance with the protocol or interpretation of results, except for the following:\n\n   1. Curatively treated localised basal cell carcinoma or localised squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ \u002F low risk carcinoma of the prostate requiring only observation, as well as untreated low grade lymphoma except chronic lymphocytic leukemia.\n   2. Other cancers not specified above that have been curatively treated by surgery and\u002For radiation therapy from which patient is disease-free for ≥2 years (≥5 years for those treated with chemotherapy) without further treatment or which are not expected to limit survival to \\\u003C 2 years.\n8. Received a live virus vaccination within 28 days of randomization.\n9. Known history of infection with HIV.\n10. Any active significant infection (e.g., bacterial, viral or fungal) as assessed by the investigator.\n11. History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML).\n12. Serologic status reflecting active hepatitis B or C infection.\n\n    1. Patients who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative PCR result before randomization and must be willing to undergo DNA PCR testing during the study. Those who are HBsAg-positive or hepatitis B PCR positive will be excluded.\n    2. Patients who are hepatitis C antibody positive will need to have a negative PCR result before randomization. Those who are hepatitis C PCR positive will be excluded.\n13. History of stroke or intracranial hemorrhage within 6 months before randomization.\n14. History of clinically relevant bleeding diathesis (e.g., hemophilia, von Willebrand disease).\n15. Major surgical procedure within 30 days before randomization. Note: If a patient had major surgery, they must have recovered adequately from any toxicity and\u002For complications from the intervention before the first dose of study drug.\n16. Breastfeeding or pregnant women.\n17. Current life-threatening illness, medical condition, organ system dysfunction, social, geographical or economic condition which, in the Investigator's opinion, could compromise the patient's safety or put the study at risk.\n18. Diagnosis of primary central nervous system lymphoma or secondary central nervous system or meningeal involvement by lymphoma\n19. Diagnosis of Richter's Transformation\u002Ftransformed CLL Prior\u002FConcomitant therapy\n20. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists. Patients using therapeutic low molecule weight heparin, direct oral anticoagulants or low dose aspirin will be eligible. Switching from vitamin K antagonists to one of the allowed anticoagulants above prior to trial entry is permitted.\n21. Requires treatment with a strong cytochrome P450 3A (CYP3A) inhibitor or inducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited. See details in section 9.12.1.\n22. Prior exposure to a BTK inhibitor.\n23. Prior anthracycline use ≥300 mg\u002Fm2.\n24. Already initiated lymphoma therapy except for steroid (max. total dose of 1000mg), vincristine (max. 1 mg once) or rituximab (max. 375mg\u002Fm2) prephase.\n25. Concurrent participation in another therapeutic clinical trial.\n26. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Patients receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrolment into this study.\n27. Received any investigational drug within 30 days or 5 half-lives (whichever is shorter) before first dose of study drug.","ALL","61 Years",{"count":20,"type":21},330,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aims to answer is whether progression free survival kann be prolonged with the addition of Acalabrutinib.\n\nParticipants will be randomised to receive either R-miniCHOP alone or R-miniCHOP with Acalabrutinib.",[27,28],"Large B-cell Lymphoma","Diffuse Large B Cell Lymphoma",[30,31,32,33,34,35,36,37,38],"Diffuse large B cell lymphoma","Older adults","Geriatric","Large B cell lymphoma","Aggressive B cell lymphoma","Acalabrutinib","R-miniCHOP","R-mini-CHOP","BTK inhibitor","RECRUITING","2026-06-24",{"date":42,"type":43},"2026-06-29","ACTUAL",{"date":45,"type":43},"2023-06-07",{"date":47,"type":21},"2029-02",{"name":49,"class":50},"Universität des Saarlandes","OTHER",17,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100643170","mobile-geriatric-unit-mgu-to-reduce-hospitalisations-in-nursing-home-residents-100643170","NCT07634757","Mobile Geriatric Unit (MGU) to Reduce Hospitalisations in Nursing Home Residents","Mobile Geriatric Unit (MGU) to Reduce Hospitalisations in Nursing Home Residents: A Prospective Observational Before-After Study","MGU","Inclusion Criteria:\n\n* Residents of participating nursing homes\n* Informed consent from participant or legal representative\n\nExclusion Criteria:\n\n* Acute life-threatening conditions requiring immediate hospitalisation",{"count":61,"type":21},4907,"OBSERVATIONAL","This prospective observational before-after study evaluates the impact of a Mobile Geriatric Unit (MGU) on hospitalisation rates among nursing home residents. The study includes a 12-month control phase with usual care followed by a 12-month intervention phase during which the MGU is implemented. The MGU provides advanced on-site diagnostics and telemedicine-supported specialist consultation within nursing homes.",[65,66],"Nursing Home Care","Hospitalisation Prevention",[68,69,70,71,72],"Nursing home","Geriatrics","Telemedicine","Hospitalisation","Mobile diagnostics","NOT_YET_RECRUITING","2026-06-08",{"date":76,"type":43},"2026-06-10",{"date":78,"type":21},"2026-09-01",{"date":80,"type":21},"2028-03",{"name":49,"class":50},1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":90,"targetDuration":92,"studyType":62,"phases":4,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":82},"100356599","the-homburg-keratoconus-center-hkc-100356599","NCT03923101","The Homburg Keratoconus Center (HKC)","The Homburg Keratoconus Center (HKC) - a Keratoconus Observation Study","Inclusion Criteria:\n\n* All Keratoconus patients presenting in the department of ophthalmology, Saarland University Medical Center, Homburg, Saarland, Germany.\n\nExclusion Criteria:\n\n* Patients without Keratoconus.",{"count":91,"type":21},5000,"10 Years","Aim of this study is to conduct longitudinal and cross-sectional analyses about the corneal ectatic disease Keratoconus based on data obtained from Keratoconus patients in the Homburg Keratoconus Center (HKC).\n\nThe Homburg Keratoconus Center (HKC) was founded in 2010 and, up to now, comprises more than 3,000 Keratoconus patients. Topographic, tomographic and biomechanic characteristics of the disease are being analyzed with the intention to elucidate how the disease begins and develops during lifetime.",[95],"Keratoconus",[95,97,98,99,100,101,102],"Crosslinking","Intracorneal ring segments","Gas-permeable rigid contact-lenses","Penetrating Keratoplasty","Deep anterior lamellar Keratoplasty","ABCD Grading System","2026-04-22",{"date":105,"type":43},"2026-04-27",{"date":107,"type":43},"2011-01-01",{"date":109,"type":21},"2036-01-01",{"name":49,"class":50},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":122,"studyType":62,"phases":4,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":132,"locationsCount":82},"100315074","the-german-keratoplasty-registry-of-the-german-ophthalmological-society-dog-100315074","NCT03381794","The German Keratoplasty Registry of the German Ophthalmological Society (DOG)","Trends in Corneal Transplantation From 2001 in Germany: Reports of the DOG-Section Cornea and Its Keratoplasty Registry","Inclusion Criteria:\n\nAll patients in Germany treated with the different types of corneal transplantation since 2001.\n\nExclusion Criteria:\n\nPatients without corneal transplantation.","1 Year","100 Years",{"count":121,"type":21},100000,"16 Years","Aim of this study is to reflect on the changing trends in absolute numbers, surgical techniques and indications of corneal transplantations being performed in Germany.\n\nThe Section Cornea of the German Ophthalmological Society provides interim-assessments on a regular basis about the most up-to-date results of this long-term study.",[125],"Corneal Transplantation",[127],"Keratoplasty Registry, PKP, DSAEK, DMEK, DALK",{"date":105,"type":43},{"date":130,"type":43},"2001-01-01",{"date":109,"type":21},{"name":49,"class":50},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":82},"100633755","time-restricted-feeding-in-masld-100633755","NCT07530809","Time-restricted Feeding in MASLD","The Impact of Time-restricted Feeding on Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","MASLD-Interval","Inclusion Criteria:\n\n* 18 and 75 years\n* Body mass index (BMI) \\> 25 kg\u002Fm²\n* MASLD grade 3 with CAP ≥ 280 dB\u002Fm, excluding liver damage\n* Liver stiffness \\\u003C 13 kPa\n* Ability to understand the study and the individual consequences of participating in the study\n* Signed and dated consent form before the start of any study activity\n\nExclusion Criteria:\n\n* Hepatocellular carcinoma or non-curatively treated carcinomas\n* Alcohol consumption \\>20 g (women) and \\>30 g (men) per day\n* Other liver diseases (HBV, HCV, HDV, HEV, HIV), autoimmune diseases or chronic cholestatic liver disease, hereditary haemochromatosis, Wilson's disease, α-1-antitrypsin deficiency\n* Medications that cause liver disease or secondary NAFLD (e.g. tamoxifen, systemic corticosteroids, methotrexate, tetracyclines, oestrogens, valproic acid)\n* Body weight changes of \\> 5% in the last 6 months\n* Statins and\u002For other lipid-lowering drugs, if these have not been taken in a stable dose for at least 4 weeks\n* Uncontrolled type 2 diabetes defined as HbA1c value \\> 9.0% or insulin-dependent type 2 diabetes\n* Pregnancy\n* Immunological or inflammatory diseases (e.g. systemic lupus erythematosus)\n* Following a restrictive, special diet\n* Patients who have undergone organ transplants\n* Lack of or absence of capacity to give consent","18 Years","75 Years",{"count":144,"type":21},120,[146],"NA","The recommended treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) currently focuses on lifestyle changes, including dietary adjustments and increased physical activity. Intermittent fasting is a specific dietary approach in which food intake is restricted for certain periods. Recent scientific evidence suggests that intermittent fasting can positively influence body weight, insulin resistance, and markers of inflammation.\n\nThis study will examine whether restricting energy intake to approximately 600 kcal on two days per week has beneficial effects on MASLD. The nutritional framework is based on the guidelines of the German Nutrition Society (DGE) for a healthy diet (10 rules for healthy eating). Following a two-week introduction to these DGE recommendations, participants will be randomly assigned to one of two treatment groups.\n\nIn the intervention group, participants follow a 5:2 intermittent fasting regimen, eating without restrictions on five days per week and limiting intake to about one-quarter of their usual daily energy (≈600 kcal) on two non-consecutive days. In the control group, participants follow a healthy diet according to DGE guidelines without restrictions on timing or energy intake.",[149],"Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)",[151,152,153,154,155,156,157,158,159],"time-restricted feeding","intermittend fasting","5:2 fasting","steatotic liver disease","MASLD","liver health","dietary intervention","nutrition","lifestyle intervention","2026-04-08",{"date":162,"type":43},"2026-04-15",{"date":164,"type":43},"2025-10-15",{"date":166,"type":21},"2029-05-15",{"name":49,"class":50},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},"100594978","phase-3-re-radiochemotherapy-and-pembrolizumab-vs-immunochemotherapy-for-locoregionally-recurrent-pd-l1-positive-cps1-hnscc-100594978","NCT07026474","Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC","Randomized Phase III Trial of Sequential Re-Radiochemotherapy and Pembrolizumab Versus Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive HNSCC (CPS≥1)","RePaIr-HN","Inclusion Criteria:\n\n* Written informed consent obtained from the subject prior to performing any protocol-related procedures.\n* Age ≥ 18 years at time of study entry.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.\n* Locoregionally recurrent or second primary HNSCC.\n* Histological confirmation of HNSCC.\n* Tumor is surgically not resectable or surgical resection bears great potential for relevant functional morbidity or patient refuses surgery.\n* No distant metastases (cM0).\n* PD-L1 combined positive score (CPS) ≥1 according to local pathological PD-L1 assessment. A validated test must be used in an accredited laboratory.\n* Prior radio(chemo)therapy of the neck (time interval ≥ 6 months).\n* Adequate normal organ and marrow function as defined: Haemoglobin ≥ 9.0 g\u002FdL; Leukocytes (WBC) ≥ 3,000 per mm3or Neutrophils ≥ 1,500 per mm3; Platelet count \\> 100,000 per mm3.\n* Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of haemolysis or hepatic pathology).\n* AST (SGOT) \u002F ALT (SGPT) ≤ 2.5 x institutional ULN.\n* Creatinine Clearance ≥ 40ml\u002Fmin (calculated from serum creatinine using the Cockcroft-Gault formula).\n* Female subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of RT and\u002For the first dose of pembrolizumab. A highly sensitive pregnancy test must be used.\n* Female subjects of childbearing potential must be willing to use a highly effective contraceptive measure (see also Section 7.1.9 Contraception and pregnancy testing during the trial). Highly effective contraception is required for the course of the trial through 120 days after the last dose of trial therapy.\n* Generative male subjects must agree to use a highly effective method of contraception (see also Section 7.1.9 Contraception and pregnancy testing during the trial), starting with the first dose of trial therapy through 120 days after the last dose of trial therapy.\n* Subject is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits and examinations including.\n\nExclusion Criteria:\n\n* Prior radio(chemo)therapy of the neck less than 6 months ago.\n* Distant metastases (cM1).\n* Is currently participating and receiving trial therapy or has participated in a trial of an investigational agent and received trial therapy or used an investigational device within 4 weeks of the first dose of treatment.\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of trial treatment. The following are exceptions to this criterion:\n\n  1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\n  2. Systemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or its equivalent\n  3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).\n* Prior chemotherapy or targeted small molecule therapy within 2 weeks or anti-cancer monoclonal antibody (mAb) within 4 weeks prior to trial day 1 or who has not recovered from AEs due to a previously administered agent. (Subjects with ≤ grade 2 neuropathy are an exception to this criterion and may qualify for the trial.)\n* History or concurrent other malignancy. Exceptions include patients, who have been disease free for at least 3 years. Further exceptions are completely resected basal cell carcinoma or squamous cell carcinoma of the skin or successfully treated in situ carcinoma.\n* Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* History of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, non-infectious pneumonitis.\n* Has an active or chronic infection requiring systemic antibacterial, antifungal or antiviral therapy within 14 days prior to randomization or first dose of study drugs.\n* Known hypersensitivity to the active substances or to any of the excipients.\n* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n* Infection with human immunodeficiency virus (HIV) (HIV 1\u002F2 antibodies).\n* Active hepatitis B (e.g., HBsAg reactive) or hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n* Live vaccine within 30 days of planned start of trial therapy.\n* Performance status of \\>2 on the ECOG Performance Scale.\n* Prior treatment with a PD-1\u002FPD-L1 antibody in primary treatment of locally advanced HNSCC less than 6 months ago.",{"count":177,"type":21},214,[24],"Prospective, open-label, randomized controlled phase III trail that aims to investigate whether Re-Radiochemotherapy (Re-RCT) and sequential immunotherapy with pembrolizumab improves overall survival compared to the standard treatment with pembrolizumab alone (± chemotherapy) in locoregionally recurrent PD-L1 positive (CPS≥1) HNSCC.",[181],"Recurrent Head and Neck Squamous Cell Carcinoma","2026-02-27",{"date":184,"type":43},"2026-03-02",{"date":186,"type":43},"2025-10-30",{"date":188,"type":21},"2032-12-31",{"name":49,"class":50},18,{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":199,"sex":17,"minAge":141,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":208,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":82},"100345077","research-for-pathophysiology-of-cancer-related-fatigue-crf-and-chronic-fatigue-cfsme-100345077","NCT03773003","Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS\u002FME)","Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS\u002FME) by Lipidomics, Metabolomics, Microbiome and Exome Analysis and Investigation of Clinical Improvement Under Administration of Probiotics","IMPROFA","Inclusion Criteria:\n\n* histologically, cytologically or radiologically confirmed tumor disease\n* indication for chemotherapy\n* Written consent to participation\n\nExclusion Criteria:\n\n* chronic-inflammatory bowel disease\n* pregnancy",true,"80 Years",{"count":202,"type":21},150,[146],"Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue Syndrome (CFS\u002FME) by Lipidomics, Metabolomics, Intestinal and Peritoneal Microbiome Analysis and Exome Analysis and Investigation of a Possible Benefit of Probiotics.",[206,207],"Cancer Related Fatigue","Fatigue Syndrome, Chronic",[209],"Cancer Fatigue, Chronic Fatigue","2025-05-22",{"date":212,"type":43},"2025-05-29",{"date":214,"type":43},"2021-07-20",{"date":216,"type":21},"2025-12-01",{"name":49,"class":50},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":82},"100426803","corona-in-the-saarland-100426803","NCT04837755","CORONA in the Saarland","CORSAAR","Inclusion Criteria:\n\nall form of COVID-19 including long-COVID-19\n\nExclusion Criteria:\n\n\\-","0 Years","110 Years",{"count":228,"type":21},300,"The CORSAAR study is an observational, prospective study to investigate the natural biology of COVID-19",[231],"Covid19","2025-05-21",{"date":234,"type":43},"2025-05-25",{"date":236,"type":43},"2020-03-01",{"date":238,"type":21},"2025-12-31",{"name":49,"class":50},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":250,"conditions":251,"keywords":256,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":82},"100582641","sex-differences-in-prehospital-stroke-medicine-100582641","NCT06865950","Sex diffErences in prehoSpitAl Stroke MEdicine","Sex Differences in Prehospital Acute Management of Suspected Stroke Patients","SESAME","Inclusion Criteria:\n\n* For all participants:\n* Adults aged 18 years of age and older\n* Emergency call to the national emergency telephone number because of acute symptoms\n* EMS treatment\n\nFor cohort 1:\n\n\\- Working diagnosis of acute stroke or TIA raised by the emergency medical dispatch centre\n\nFor cohort 2:\n\n\\- Working diagnosis of acute stroke or TIA raised by the EMS personnel at the emergency site\n\nFor cohort 3:\n\n\\- Hospital confirmed diagnosis of acute stroke or TIA\n\nExclusion Criteria:\n\n* Patients, who have acute stroke symptoms but do not involve the EMS and make their way to hospital themselves",{"count":249,"type":21},2000,"Background: Stroke is a leading cause for individual, family and societal harm with huge health-economic impact. Immediate and correct prehospital acute stroke pathway initiation is key for treatment success.\n\nEvidence points towards sex inequity in management pathways of acute stroke care. A complicating factor in acute stroke management is the diversity in clinical presentation among patients of different sex. This increases the challenges of correct prehospital identification.\n\nMost of the currently available data on male and female differences in acute stroke management come from patients with hospital-confirmed stroke. Little to no information is available about sex-related management differences of patients with prehospital suspected stroke, often missed by stroke quality databases.\n\nObjectives: To identify sex differences in EMS-delivered prehospital diagnostic accuracy and management of patients with suspected or confirmed acute stroke.\n\nMethods: International project collaboration to conduct a cross-regional cohort analysis of patients with a prehospital working diagnosis of stroke and\u002For hospital-confirmed stroke diagnosis.\n\nRelevance: More information and details about the reasons for a potential prehospital treatment inequity are a necessary next step for any improvement and subsequent development of structured training programmes for emergency medical service personnel. This project is the first large-scaled international collaboration addressing sex differences in prehospital stroke care. With this approach the project will not only lead to more urgently needed information, but will also serve as a lighthouse project for raising general awareness for this topic.",[252,253,254,255],"Stroke Acute","Emergency Medical Services","Sex Characteristics","Prehospital Setting",[257,258,259,260,261],"stroke","sex differences","ambulance service","stroke treatment","inequality","2025-05-15",{"date":232,"type":43},{"date":265,"type":43},"2025-05-01",{"date":267,"type":21},"2026-12-31",{"name":49,"class":50},{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":276,"targetDuration":92,"studyType":62,"phases":4,"briefSummary":278,"conditions":279,"keywords":284,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":300},"100585837","long-term-follow-up-to-determine-outcome-in-liver-disease-love-study-100585837","NCT06907563","Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)","LOVE","Inclusion Criteria:\n\n* Previous Informed consent for cohort studies\n* \\> 18 years of age\n* Diagnosis of SLD (MASLD, MetALD, ALD)\n\nExclusion Criteria:\n\n* No consent for previous cohort studies\n* \\\u003C 18 years of age\n* No Diagnosis of SLD (MASLD, MetALD, ALD)",{"count":277,"type":21},30000,"The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years. At current limited data on liver-specific and overall outcome in patients with MASLD, MetALD and ALD are available. Liver histology is the only accepted surrogate to reasonably likely predict outcomes in patients with non-cirrhotic liver disease and is currently used in regulatory trials. To overcome the limitations of liver biopsy and use validated non-invasive tests (NITs) to predict outcomes, the LOVE study will be conducted based on existing cohort studies in well pheno- and genotyped patients and will inform on the relevant outcomes based on baseline and ongoing biomarker assessment. The overarching goal is to qualify a NIT for patient identification and preventive measures in the regulatory context.",[280,281,282,283],"Steatotic Liver Disease","MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)","Steatotic Liver Disease of Mixed Origin (MetALD)","ALD - Alcoholic Liver Disease",[285,286,287,155,288,289,290,291],"MASH","SLD","NITs","ALD","MetALD","Metabolism","Liver","2025-03-26",{"date":294,"type":43},"2025-04-02",{"date":296,"type":21},"2025-04-15",{"date":298,"type":21},"2035-12-31",{"name":49,"class":50},4,{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":309,"targetDuration":311,"studyType":62,"phases":4,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":82},"100551363","adherence-to-medication-in-patients-with-acute-decompensated-heart-failure-100551363","NCT06459115","Adherence to Medication in Patients With Acute Decompensated Heart Failure","Adherence to Medication in Patients With Acute Decompensated Heart Failure: a Cross-sectional Study at the Emergency Department (ADHF-ED= Adherence to Medication in Patients With Acute Decompensated Heart Failure at the Emergency Department)","ADHF-ED","Inclusion Criteria:\n\n* age ≥18 years of age\n* known chronic heart failure irrespective of ejection fraction (heart failure with reduced, mildly reduced, or preserved ejection fraction)\n* requirement of intravenous diuretics (outpatient or stationary treatment)\n* stable heart failure medication \\>2 weeks\n* ≥1 sign of volume overload (peripheral edema, jugular venous distension, pulmonary rales, ascites, or demonstration of pulmonary venous congestion on chest X-ray)\n* elevated natriuretic peptides (N-terminal pro brain natriuretic peptide= nt-pro-BNP ≥125 pg\u002Fml)\n\nExclusion Criteria:\n\n\\- Not able to give written informed consent",{"count":310,"type":21},100,"7 Days","Every day, patients present to emergency department due to acute heart failure. There are many causes for decompensation. One possible cause is a lack of adherence to heart failure medication (prognosis-improving medications and diuretics). The aim of this study is to directly measure adherence in patients with acute heart failure (gold standard of adherence measurement using liquid chromatography coupled to high-resolution mass spectrometry= LC-HRMS\u002FMS) at the emergency department. Questionnaires are used to investigate possible factors influencing adherence.",[314],"Acute Decompensated Heart Failure",[314,316,317],"Adherence","Emergency department","2024-06-17",{"date":320,"type":43},"2024-06-20",{"date":322,"type":43},"2023-02-01",{"date":324,"type":21},"2024-12-31",{"name":49,"class":50},{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":348},"100533276","phase-2-durvalumab-with-consolidative-radiochemotherapy-and-ablative-stereotactic-radiotherapy-in-oligometastatic-es-sclc-100533276","NCT06223711","Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC","Durvalumab (MEDI4736) in Combination With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Extensive Stage SCLC","Inclusion Criteria:\n\nFor inclusion in the study patients must fulfill all of the following criteria:\n\n1. Histologically confirmed first diagnosis of ES-SCLC according to the Veterans Administration Lung Study Group (VALG) Staging System for SCLC1 (disease extension that cannot be treated within one radiation field).\n2. Oligometastatic disease defined as follows:\n\n   * Primary tumor with or without mediastinal or supraclavicular lymph node metastases (counts as one lesion if it can be treated within one radiation field).\n   * Up to four distant tumor lesions\u002Fmetastases that can be treated with stereotactic radiotherapy (stereotactic radiotherapy of lung metastases in addition to radiochemotherapy of primary tumor should previously be discussed with the principal investigator).\n   * No cytologically confirmed malignant pleural effusion (in case of suspected malignant pleural effusion in imaging, pleurocentesis for cytological assessment is required).\n3. Stable disease (SD) or partial response (PR) according to RECIST 1.1 criteria after previous treatment with two cycles of platinum\u002Fetoposide\u002Fdurvalumab.\n4. Adequate lung function defined as forced expiratory volume in the first second (FEV1) ≥1.3 liter in spirometry.\n5. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent including European Union Data Privacy Directive obtained from the patient prior to performing any protocol-related procedures, including screening evaluations.\n6. Age \\> 18 years at time of study entry.\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n8. Body weight \\>30 kg.\n9. Adequate normal organ and marrow function as defined below:\n\n   * Hemoglobin ≥9.0 g\u002FdL\n   * White Blood Cells (WBC) ≥ 3,000 per mm3\n   * Platelet count \\>100,000 per mm3\n   * Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.\n   * AST (SGOT)\u002FALT (SGPT) ≤2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be ≤5x ULN\n   * Calculated creatinine CL\\>40 mL\u002Fmin by the Cockcroft-Gault formula\n10. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow-up.\n11. Must have a life expectancy of at least 12 weeks.\n\nExclusion Criteria:\n\nPatients should not enter the study if any of the following exclusion criteria are fulfilled:\n\n1. Participation in another clinical study with an investigational product during the last 4 weeks.\n2. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.\n3. Prior systemic anticancer therapy (chemotherapy, immunotherapy, targeted therapy), apart from two cycles of etoposide\u002Fplatinum + durvalumab (prior chemotherapy\u002F immunotherapy\u002F targeted therapy for other malignancy treated with curative intent ≥5 years ago is no exclusion criterion).\n4. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous chemo-immunotherapy (2 cycles of platinum\u002Fetoposide + durvalumab) with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria\n\n   1. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.\n   2. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician.\n5. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.\n6. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.\n7. Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.\n8. History of allogenic organ transplantation.\n9. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease (e.g., colitis or Crohn's disease), diverticulitis (with the exception of diverticulosis), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.). The following are exceptions to this criterion:\n\n   1. Patients with vitiligo or alopecia\n   2. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement\n   3. Any chronic skin condition that does not require systemic therapy\n   4. Patients without active disease in the last 5 years may be included but only after consultation with the study physician\n   5. Patients with celiac disease controlled by diet alone\n10. Uncontrolled intercurrent illness, including but not limited to, ongoing or active symptomatic infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, QTcF (QT interval on ECG corrected using the Frederica's formula) \\>470 ms, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.\n11. History of another primary malignancy except for\n\n    1. Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence\n    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n    3. Adequately treated carcinoma in situ without evidence of disease\n12. History of leptomeningeal carcinomatosis.\n13. History of active primary immunodeficiency.\n14. Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of anti HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n15. Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1\u002F2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings).\n16. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:\n\n    1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\n    2. Systemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or its equivalent\n    3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n17. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.\n18. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.\n19. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n20. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment.\n21. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.\n22. Known allergy or hypersensitivity to IP or any excipient.",{"count":334,"type":21},43,[336],"PHASE2","Open-label, single-arm, prospective multicenter phase II clinical trial to determine the efficacy of immunotherapy with durvalumab concomitant with radiochemotherapy, followed by durvalumab maintenance therapy in combination with stereotactic radiotherapy in extensive stage SCLC",[339],"Extensive-stage Small-cell Lung Cancer","2024-04-04",{"date":342,"type":43},"2024-04-05",{"date":344,"type":43},"2023-10-06",{"date":346,"type":21},"2027-12",{"name":49,"class":50},5,{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":356,"targetDuration":358,"studyType":62,"phases":4,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":82},"100529959","homburg-renal-evaluation-study-on-the-clinical-utility-of-early-aki-diagnosis-100529959","NCT06180551","Homburg Renal Evaluation Study on the Clinical Utility of Early AKI Diagnosis","RESCUE-AKI","Inclusion Criteria:\n\n* Patients treated on the intensive care units of Saarland University Hospital.\n\nExclusion Criteria:\n\n* Patients on renal replacement treatment before admission to the intensive care unit.\n* Patients with chronic kidney disease stage CKD G3b or below.\n* Known kidney disease.\n* Kidney transplantation.\n* Intoxications leading to dialysis treatment.\n* Participation in other clinical trials.",{"count":357,"type":21},1000,"2 Years","Critically ill patients are at risk of developing a sudden decrease of kidney function which may be detected by a decrease in urine output or is diagnosed on the basis of blood tests for substances normally eliminated by the kidney, primarily creatinine.\n\nBecause it takes about 24 hours for the creatinine level to rise, even if both kidneys have ceased to function, better markers are needed.\n\nThis trial is investigating if the marker urinary dickkopf-3 (uDKK3) allows an early prediction of a sudden decrease of kidney function.",[361],"Acute Kidney Injury","2023-12-12",{"date":364,"type":43},"2023-12-22",{"date":366,"type":43},"2023-12-01",{"date":368,"type":21},"2027-06",{"name":49,"class":50},""]